TAK-653

Also named Osavampator and NBI-1065845.
Selective positive allosteric modulator (PAM) of the AMPA receptor.
Potentiate the effects of agonists at the main site of the AMPA receptor by slowing the rate of desensitization and internalization of the receptor.
Terminal half-life is 33.1–47.8 hours.
Possesses minimal direct AMPA agonist properties.
Provides a 419-fold safety margin against convulsions relative to therapeutic doses in rats.